Redburn Atlantic analyst Issie Kirby upgraded Alcon (ALC) to Buy from Neutral with a price target of CHF 93, up from CHF 80. The firm views fiscal 2025 as a pivotal year for Alcon with multiple new launches. The surgical equipment and dry eye pharma launches are the most material, the analyst tells investors in a research note. It predicts Alcon’s organic growth will accelerate on launch momentum.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener